Rupall is commonly used across domains where additional symptomatic support is needed for conditions associated with acute or episodic changes. It is applied in situations involving certain distressing symptoms, generally covering conditions like allergic rhinitis and chronic spontaneous urticaria (CSU). It is often used when symptoms intensify and supportive relief is needed.

---

Addressing Nasal and Respiratory Allergy Symptoms

The medicine may assist with conditions involving episodic or fluctuating manifestations, such as allergic rhinitis (seasonal or perennial). It is relevant for managing symptoms that interfere with daily comfort, including those related to the nose and eyes. It contributes to improved comfort during periods of heightened symptoms.

---

Managing Hives and Allergic Skin Manifestations

The medicine is commonly used across conditions presenting with acute episodes, such as chronic spontaneous urticaria (CSU), marked by increased discomfort or tension. It is relevant for easing symptoms related to inflammatory or irritative states, such as bothersome skin manifestations. It provides support that helps ease the overall symptom burden during difficult episodes.

Quick Fact: May assist with bothersome skin symptoms

Who Can and Cannot Use Rupall? (Rupatadine)

The eligibility for Rupall use is strictly defined by regulatory documents, establishing who is permitted to use the medicine and who is officially contraindicated.

Populations Prohibited (Contraindications)

Use is contraindicated in patients with a known hypersensitivity to rupatadine or to any component of the formulation. The product must also be avoided by individuals with rare hereditary problems such as galactose intolerance, total lactase deficiency, or specific sugar malabsorption disorders, with the specific disorder depending on whether the tablet or oral solution is prescribed.

Age-Based and Conditional Use

Age Group / Condition	Official Regulatory Status
Children under 2 years	Not recommended (Insufficient data)
Children 2 to 11 years	Eligible for Oral Solution only
Adolescents and Adults (12+ years)	Eligible for Tablet formulation
Elderly (65+ years)	Use with Caution
Renal or Hepatic Impairment	Not recommended (Absence of clinical experience)
Pregnancy	Preferably avoided (Precautionary measure)

Use requires caution in patients with known cardiovascular risks, such as QT interval prolongation or ongoing proarrhythmic conditions. For women who are breastfeeding, the regulatory recommendation is to either discontinue breastfeeding or discontinue the medicinal product.

Rupall (Rupatadine) is metabolized primarily by the Cytochrome P450 3A4 (CYP3A4) enzyme, which forms the basis for several clinically significant interactions. Combining Rupall with medicines that inhibit this enzyme can increase Rupall's concentration in the bloodstream, raising the risk of adverse effects.

Co-administration with potent CYP3A4 inhibitors such as ketoconazole (which increased Rupatadine exposure ten-fold in studies), itraconazole, and certain HIV protease inhibitors is generally contraindicated or not recommended. The use of moderate CYP3A4 inhibitors, including erythromycin (which increased exposure two- to three-fold) and diltiazem, should be approached with caution or avoided.

Cardiovascular and QTc Prolongation Risk

Due to the potential for QTc interval prolongation, Rupall is contraindicated for use in patients with a history of QT prolongation or when co-administered with other QTc-prolonging drugs. Medicines that can deplete electrolytes (like certain diuretics) or other conditions that increase proarrhythmic risk also require caution.

Other Interactions

Rupall should be used with caution alongside statins (HMG-CoA reductase inhibitors), as both are partly metabolized by CYP3A4 and the risk of interactions is not fully established. Grapefruit juice can also increase Rupall's systemic exposure and should not be consumed simultaneously. While Rupall at the recommended dose does not significantly increase alcohol-induced impairment, a higher dose (20 mg) has been shown to increase the effects of alcohol.

Rupall (rupatadine) functions as a dual antagonist targeting the histamine H1 receptor and the platelet-activating factor (PAF) receptor.

At the molecular level, rupatadine selectively binds to and prevents the activation of peripheral H1 receptors, thereby blocking the downstream effects of endogenously released histamine, which primarily involve Gq protein-coupled signaling cascades. Concurrently, rupatadine acts as an antagonist at the PAF receptor, a G-protein-coupled receptor, inhibiting PAF-mediated cellular responses.

Intracellularly, this dual antagonism modulates the release of multiple proinflammatory mediators. Rupatadine inhibits the degranulation of mast cells, a key source of histamine and PAF, and blocks the release of inflammatory cytokines and chemokines, such as IL-6 and IL-8, from various immune cells, including mast cells and monocytes. This action reduces the subsequent recruitment and activation of other immune cells like eosinophils and neutrophils.

System-level physiological consequences of this pharmacodynamic activity include the attenuation of histamine-induced vasodilation and increased vascular permeability, as well as the mitigation of PAF-mediated inflammatory processes, leading to modulation of local tissue edema and mucosal secretion.

How Rupall is Used: Official Administration Guidelines

The usage of Rupall (Rupatadine fumarate) is strictly governed by official instructions detailing the administration method, standardized dosage, and population constraints. The medication is authorized exclusively for the oral route of administration.

---

Dosing Schedule and Frequency

The approved dosage for Rupatadine is designed for once-daily (QD) intake across all authorized age groups. The standard regimen for adults and adolescents (12 years and older) is 10 mg. For children aged 2 to 11 years, the medication is administered via an oral solution with a weight-based dose:

• Children weighing ge 25 kg: 5 mg (5 mL) once daily.
• Children weighing ge 10 kg to < 25 kg: 2.5 mg (2.5 mL) once daily.

---

Administration Conditions

Rupatadine may be taken with or without food, offering flexibility in the daily schedule. However, official instructions emphasize the need to avoid consuming grapefruit and grapefruit juice during treatment, as these products may affect the drug's systemic exposure. For accurate dosing, the oral solution must be carefully measured using a dedicated dosing syringe, while the tablet form should be swallowed whole with liquid.

---

Population Constraints and Missed Doses

Administration of Rupall is not recommended for children under 2 years of age or for patients with known hepatic (liver) or renal (kidney) impairment due to a lack of clinical data in these specific groups. If a dose is missed, the patient should take it as soon as possible, but must not take a double dose to compensate for the forgotten one. The overall treatment duration is determined by the treating physician based on the patient's condition.

Evidence for Use in Allergic Rhinitis

Research examined Rupall in populations with allergic rhinitis, a condition characterized by fluctuating or episodic manifestations, primarily through randomized, double-blind, placebo-controlled clinical trials (RCTs). These short- and intermediate-term studies evaluated how symptoms changed over defined intervals, focusing on outcomes related to physical discomfort, such as the Total Nasal Symptom Score (TNSS), and patient-reported Quality of Life (QoL). While initial controlled research provides insight into short-term changes, there is limited information for long-term outcomes that extend beyond the standard 12-week pivotal trial duration. Furthermore, research on higher-than-standard daily doses has yielded mixed results, and certainty remains low regarding consistent findings.

---

Evidence for Use in Chronic Spontaneous Urticaria (Hives)

Research examined Rupall in populations with chronic spontaneous urticaria (CSU), a condition involving periods of heightened symptoms such as persistent itching and hives. The regulatory evidence is based on short-term, randomized, placebo-controlled clinical trials (RCTs), typically lasting four to six weeks, monitoring the Urticaria Activity Score 7 (UAS7). Studies reported how patient-reported discomfort evolved in the observed populations. While outcomes were evaluated in these short-term studies, long-term patterns of symptom change are not fully established by evidence from blinded, placebo-controlled trials, requiring reliance on data from observational settings.

---

Long-Term Studies and Follow-up Data

Studies have explored the long-term use of Rupall using observational cohorts that track continuous use for up to five years. While these studies provide context regarding continuous use, they are not structured as blinded, placebo-controlled trials. For allergic rhinitis, the efficacy RCTs typically range from 4 to 12 weeks, meaning the foundational research on long-term patterns of measured outcomes is not fully established by this type of high-certainty data.

---

Research in Specific Patient Populations

Rupall was evaluated in a range of patient groups, including adolescents (ge 12 years of age) and dedicated clinical trials for children aged 6 to 11 years. For the youngest patients (2 to 5 years), evidence is derived from extrapolation. This means that pharmacokinetic studies and safety data from older children were used to inform evaluation in the younger age group, rather than relying on dedicated efficacy trials. These results apply only to the populations studied.

---

Gaps in Evidence and Areas for Future Research

The research highlights key areas where certainty remains low. The follow-up durations were limited in many core RCTs, meaning long-term outcomes are not well characterized. Additionally, the subgroup findings are uncertain in studies exploring differences across dosing regimens. Finally, studies documenting direct comparison evidence are lacking regarding some other treatments.

Key Studies & References

1. Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria (NCT00199238)
2. Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial (2015) [Long-term observational data]

Common questions about Rupall (FAQ)

Q: How is Rupall different from other common allergy medicines like Claritin or Reactine?

Rupall is described in official documents as a dual antagonist. This means it works by targeting two inflammatory substances in the body: the histamine H1 receptor and the Platelet-Activating Factor (PAF) receptor. Many other common second-generation allergy medicines are described as primarily targeting only the H1 receptor.

---

Q: Does Rupall only treat seasonal allergies, or does it also work for year-round symptoms?

According to the official product information, Rupall is indicated for the symptomatic relief of both seasonal allergic rhinitis and perennial allergic rhinitis. Perennial allergic rhinitis is the medical term used to describe allergy symptoms that occur year-round.

---

Q: Is it safe to drink alcohol in moderation while taking Rupall?

Studies in healthy volunteers taking the standard 10 mg dose reported minimal effects on psychomotor performance when compared to alcohol intake alone. However, regulatory documents indicate that a higher dose (20 mg) was found to increase the impairment caused by the intake of alcohol. Official documents describe that caution is necessary, and the medication should be taken strictly according to the authorized dose.

---

Q: Can Rupall cause excessive drowsiness or affect my ability to drive?

The medication may cause documented side effects like somnolence (sleepiness) or dizziness. Studies involving a car-driving test using the standard 10 mg dose did not show impairment in mental alertness compared to a placebo. Official instructions indicate that caution is necessary when performing tasks that require full concentration.

---

Q: Does Rupall have a generic version available, and is it the same as the brand name?

The active substance in Rupall is Rupatadine fumarate. Regulatory databases list Rupatadine as the generic name, meaning it contains the same active medicinal substance as the branded product.

---

Q: Are headaches a common side effect of Rupall, and do they usually go away?

Headache is officially documented as a common adverse reaction to Rupall. Patient information indicates that common side effects, including headaches, are generally described as mild. Available information suggests that such effects may resolve over time.

---

Q: Can I take Rupall daily, or is it only intended for short-term use during allergy flare-ups?

Rupall is indicated for symptomatic relief of conditions like perennial allergic rhinitis and chronic urticaria, which may require continuous treatment. Research has examined continuous use of the medication in observational cohorts for durations of up to one year or longer.

---

Q: What is the Platelet-Activating Factor (PAF) that Rupall is described as blocking?

Platelet-Activating Factor (PAF) is described in medical literature as a potent inflammatory chemical and lipid mediator. This substance is released by certain immune cells and is understood to contribute to the allergic and inflammatory response in the body alongside histamine.

---

Q: How quickly does Rupall usually start working to relieve allergy symptoms?

Studies and official information indicate that Rupatadine is absorbed rapidly. Symptomatic relief is reported to typically start within 1 to 2 hours after administration.

---

Q: How long does the effect of one dose of Rupall typically last?

The antihistaminic activity of one dose is reported to be long-lasting. This extended effect can continue for up to 24 hours, supporting the approved schedule of once-daily intake.

---

Q: Does Rupall interact with any common over-the-counter pain relievers or supplements?

Official warnings describe that co-administration with strong inhibitors of the CYP3A4 enzyme should be avoided, as this may increase Rupall's concentration in the body. St. John’s wort, a common herbal supplement, is cited in regulatory sources as an example of a substance that may also affect the removal of Rupall from the body.

---

Q: Can taking Rupall interfere with the results of an allergy skin prick test?

Official information states that Rupall may interfere with the results of certain laboratory tests. This specifically includes allergy skin testing, which could potentially cause false test results.

---

Q: Is Rupall approved for relieving symptoms of eczema or general skin itching that isn't hives?

Official product information specifies that Rupall is indicated for the symptomatic relief of allergic rhinitis (including seasonal and perennial) and chronic spontaneous urticaria (hives). Information concerning other skin conditions like eczema is not within the stated indications.

---

Q: What is the difference between seasonal allergic rhinitis and perennial allergic rhinitis that Rupall treats?

Allergic rhinitis is classified as seasonal when symptoms are intermittent and related to specific seasonal allergens, such as pollen. It is classified as perennial (year-round) when symptoms are persistent and are commonly related to non-seasonal allergens like house dust mites.

---

Q: What should I do if the side effects of Rupall are disruptive or concerning?

Official guidance suggests consulting a healthcare provider if common symptoms persist or become severe. Serious side effects, such as a fast or irregular heartbeat or feeling faint, are specifically listed in official documents as requiring immediate medical care.

Official Storage and Disposal Instructions

Storage and handling of Rupall (rupatadine) must strictly follow official regulatory guidelines to maintain product stability and safety.

Formulation	Required Storage Condition
10 mg Tablets	Store at room temperature in the original outer carton to protect from light and moisture.
1 mg/ml Oral Solution	Does not require any special storage conditions.

All forms of the medicine must be stored out of the sight and reach of children. The product must not be used after the expiry date marked on the packaging. Unused or expired Rupall must not be thrown away via household waste or wastewater. Disposal should be carried out in accordance with local requirements and guidance from a pharmacist.